Expert panel recommends conditional approval to Kovyshield and Kovaxin, emergency approval set

 Expert panel recommends conditional approval to Kovyshield and Kovaxin, emergency approval set

 Expectations grow a step: Expert panel recommends conditional approval to Kovyshield and Kovaxin, emergency approval set

 The expert panel has given its recommendations to the central government on which corona will be the first vaccine in the country.  The panel has recommended conditional approval of Kovashield of Serum Institute of India and Kovaxin of Bharat Biotech.  They are expected to be approved soon.

 Three companies have sought approval so far

 So far, the Serum Institute of India (SII), Bharat Biotech and Pfizer have applied for emergency use approval.  The Serum Institute is producing a vaccine named Kovyshield.  It has been developed by Oxford University and pharma company AstraZeneca.

  Apart from the serum institute, Bharat Biotech, which manufactures indigenous vaccine covaxin, made a presentation before the panel on Wednesday.  At the same time, American company Pfizer has asked for more time to present its data.  However, Pfizer has been approved by the WHO for emergency use a day earlier.

 Dry run of vaccine across the country from tomorrow

 After approval from the expert panel, the applications of the companies will go to the Drugs Controller General of India (DCGI) for final approval.  The government is preparing to start vaccination from this month.  For this, a vaccine dry run has to be done across the country tomorrow i.e. on January 2.

 Earlier on Thursday, Drug Controller General Dr. VG Somani had said that the new year will be happy for us, because then we will have something in our hands.  It is believed that soon a vaccine may be approved.  India is the second largest country in the world affected by Corona after America.  The government has planned to vaccinate 300 million people in the next six to eight months.

 Kovyshield cheapest vaccine

 The Oxford vaccine is the government's biggest hope because of its low cost.  The company says that it will first focus on its domestic market.  It will then be exported to South Asian countries and Africa.

 The CEO of the world's largest vaccine-making company, Adar Poonawalla, reported on Monday that nearly five crore of the Oxford-AstraZeneca vaccine had already been prepared.  There are plans to make 10 crore by March next year and 30 crore by June.

 Harshvardhan said - need to prepare like election

 Union Health Minister Dr. Harsh Vardhan reviewed the preparations for the dry run with the Delhi government on Friday.  In this, he told that companies have applied to drug controllers and experts for approval of the vaccine.  Their data is being closely studied.  A list of health workers has been made for vaccination.  It will be uploaded on the Kovid platform.

 He said that as we prepare for elections, the members of the medical team also need to be trained.  Therefore, after training more than 2,000 master trainers at the national level, training programs are going on in more than 700 districts.

 Emergency use approved in these countries

 In the US, Pfizer and Moderna's vaccine has received emergency use approval.

 The UK has approved the Pfizer and AstraZeneca vaccines.  Vaccination is going on here.

 China has recently approved the vaccine of indigenous company Sinopharm with certain conditions.

 Mass vaccination has also been introduced in Russia through indigenous vaccine Sputnik V.

 Canada has approved the vaccines of Pfizer and BioNotech.